Phase II trial of temsirolimus in patients with metastatic breast cancer

Gini F. Fleming, Cynthia X. Ma, Dezheng Huo, Husain Sattar, Maria Tretiakova, L. Lin, Olwen M. Hahn, F. O. Olopade, R. Nanda, Philip C. Hoffman, M. J. Naughton, Timothy Pluard, Suzanne D. Conzen, Matthew J. Ellis

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single arm phase II study of the rapamycin analog, temsirolimus, at a dose of 25 mg weekly, in women with pretreated breast cancers that were positive for ER, PR, or HER2. Archived formalin-fixed paraffin embedded tumor was collected for immunohistochemical evaluation of components of the PI3K/Akt/mTOR pathway and PIK3CA mutation analysis. Thirty-one patients were enrolled. There were no major objective responses; however, three patients had stable disease for over 24 weeks. Twenty-three tumor samples were available for mutational analysis. There were five tumors with PIK3CA mutations; no association was found between prolonged stable disease and PIK3CA mutation or any immunohistochemical marker. There was a trend toward improved progression free survival (PFS) for patients with positive nuclear staining for phospho-Akt308. One patient remains on study four and a half years after starting therapy; her tumor did not have a PIK3CA mutation. We conclude that single agent temsirolimus has minimal activity in a population of women with heavily pretreated breast cancer. We found no evidence that either absence of immunohistochemical staining for PTEN or mutations in the hotspot domains of PIK3CA in the primary tumor were associated with clinical benefit.

Original languageEnglish (US)
Pages (from-to)355-363
Number of pages9
JournalBreast Cancer Research and Treatment
Volume136
Issue number2
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Breast Neoplasms
Mutation
Sirolimus
Neoplasms
Estrogen Receptors
Staining and Labeling
temsirolimus
Phosphatidylinositol 3-Kinases
Paraffin
Formaldehyde
Disease-Free Survival
Population
Genes
Therapeutics

Keywords

  • Breast cancer
  • PIK3CA
  • PTEN
  • Rapamycin
  • Temsirolimus
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fleming, G. F., Ma, C. X., Huo, D., Sattar, H., Tretiakova, M., Lin, L., ... Ellis, M. J. (2012). Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 136(2), 355-363. https://doi.org/10.1007/s10549-011-1910-7

Phase II trial of temsirolimus in patients with metastatic breast cancer. / Fleming, Gini F.; Ma, Cynthia X.; Huo, Dezheng; Sattar, Husain; Tretiakova, Maria; Lin, L.; Hahn, Olwen M.; Olopade, F. O.; Nanda, R.; Hoffman, Philip C.; Naughton, M. J.; Pluard, Timothy; Conzen, Suzanne D.; Ellis, Matthew J.

In: Breast Cancer Research and Treatment, Vol. 136, No. 2, 01.11.2012, p. 355-363.

Research output: Contribution to journalArticle

Fleming, GF, Ma, CX, Huo, D, Sattar, H, Tretiakova, M, Lin, L, Hahn, OM, Olopade, FO, Nanda, R, Hoffman, PC, Naughton, MJ, Pluard, T, Conzen, SD & Ellis, MJ 2012, 'Phase II trial of temsirolimus in patients with metastatic breast cancer', Breast Cancer Research and Treatment, vol. 136, no. 2, pp. 355-363. https://doi.org/10.1007/s10549-011-1910-7
Fleming, Gini F. ; Ma, Cynthia X. ; Huo, Dezheng ; Sattar, Husain ; Tretiakova, Maria ; Lin, L. ; Hahn, Olwen M. ; Olopade, F. O. ; Nanda, R. ; Hoffman, Philip C. ; Naughton, M. J. ; Pluard, Timothy ; Conzen, Suzanne D. ; Ellis, Matthew J. / Phase II trial of temsirolimus in patients with metastatic breast cancer. In: Breast Cancer Research and Treatment. 2012 ; Vol. 136, No. 2. pp. 355-363.
@article{27a012b484184dd09aa2cf625b750c67,
title = "Phase II trial of temsirolimus in patients with metastatic breast cancer",
abstract = "Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single arm phase II study of the rapamycin analog, temsirolimus, at a dose of 25 mg weekly, in women with pretreated breast cancers that were positive for ER, PR, or HER2. Archived formalin-fixed paraffin embedded tumor was collected for immunohistochemical evaluation of components of the PI3K/Akt/mTOR pathway and PIK3CA mutation analysis. Thirty-one patients were enrolled. There were no major objective responses; however, three patients had stable disease for over 24 weeks. Twenty-three tumor samples were available for mutational analysis. There were five tumors with PIK3CA mutations; no association was found between prolonged stable disease and PIK3CA mutation or any immunohistochemical marker. There was a trend toward improved progression free survival (PFS) for patients with positive nuclear staining for phospho-Akt308. One patient remains on study four and a half years after starting therapy; her tumor did not have a PIK3CA mutation. We conclude that single agent temsirolimus has minimal activity in a population of women with heavily pretreated breast cancer. We found no evidence that either absence of immunohistochemical staining for PTEN or mutations in the hotspot domains of PIK3CA in the primary tumor were associated with clinical benefit.",
keywords = "Breast cancer, PIK3CA, PTEN, Rapamycin, Temsirolimus, Treatment",
author = "Fleming, {Gini F.} and Ma, {Cynthia X.} and Dezheng Huo and Husain Sattar and Maria Tretiakova and L. Lin and Hahn, {Olwen M.} and Olopade, {F. O.} and R. Nanda and Hoffman, {Philip C.} and Naughton, {M. J.} and Timothy Pluard and Conzen, {Suzanne D.} and Ellis, {Matthew J.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/s10549-011-1910-7",
language = "English (US)",
volume = "136",
pages = "355--363",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Phase II trial of temsirolimus in patients with metastatic breast cancer

AU - Fleming, Gini F.

AU - Ma, Cynthia X.

AU - Huo, Dezheng

AU - Sattar, Husain

AU - Tretiakova, Maria

AU - Lin, L.

AU - Hahn, Olwen M.

AU - Olopade, F. O.

AU - Nanda, R.

AU - Hoffman, Philip C.

AU - Naughton, M. J.

AU - Pluard, Timothy

AU - Conzen, Suzanne D.

AU - Ellis, Matthew J.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single arm phase II study of the rapamycin analog, temsirolimus, at a dose of 25 mg weekly, in women with pretreated breast cancers that were positive for ER, PR, or HER2. Archived formalin-fixed paraffin embedded tumor was collected for immunohistochemical evaluation of components of the PI3K/Akt/mTOR pathway and PIK3CA mutation analysis. Thirty-one patients were enrolled. There were no major objective responses; however, three patients had stable disease for over 24 weeks. Twenty-three tumor samples were available for mutational analysis. There were five tumors with PIK3CA mutations; no association was found between prolonged stable disease and PIK3CA mutation or any immunohistochemical marker. There was a trend toward improved progression free survival (PFS) for patients with positive nuclear staining for phospho-Akt308. One patient remains on study four and a half years after starting therapy; her tumor did not have a PIK3CA mutation. We conclude that single agent temsirolimus has minimal activity in a population of women with heavily pretreated breast cancer. We found no evidence that either absence of immunohistochemical staining for PTEN or mutations in the hotspot domains of PIK3CA in the primary tumor were associated with clinical benefit.

AB - Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single arm phase II study of the rapamycin analog, temsirolimus, at a dose of 25 mg weekly, in women with pretreated breast cancers that were positive for ER, PR, or HER2. Archived formalin-fixed paraffin embedded tumor was collected for immunohistochemical evaluation of components of the PI3K/Akt/mTOR pathway and PIK3CA mutation analysis. Thirty-one patients were enrolled. There were no major objective responses; however, three patients had stable disease for over 24 weeks. Twenty-three tumor samples were available for mutational analysis. There were five tumors with PIK3CA mutations; no association was found between prolonged stable disease and PIK3CA mutation or any immunohistochemical marker. There was a trend toward improved progression free survival (PFS) for patients with positive nuclear staining for phospho-Akt308. One patient remains on study four and a half years after starting therapy; her tumor did not have a PIK3CA mutation. We conclude that single agent temsirolimus has minimal activity in a population of women with heavily pretreated breast cancer. We found no evidence that either absence of immunohistochemical staining for PTEN or mutations in the hotspot domains of PIK3CA in the primary tumor were associated with clinical benefit.

KW - Breast cancer

KW - PIK3CA

KW - PTEN

KW - Rapamycin

KW - Temsirolimus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84868195516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868195516&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1910-7

DO - 10.1007/s10549-011-1910-7

M3 - Article

C2 - 22245973

AN - SCOPUS:84868195516

VL - 136

SP - 355

EP - 363

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -